Search - tctmd.com

Displaying 21 - 40 of 80

Sort: Relevancy | Date

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

News Daily News

HFSA Stats 2024 a ‘Call to Action’ Against Rising Tide of HF

October 01, 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

News Conference News HFSA 2024

Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity

October 01, 2024

HFSA Cancels Annual Meeting Due to Looming Hurricane

News Daily News

HFSA Cancels Annual Meeting Due to Looming Hurricane

September 26, 2024

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

News Daily News

Yes, Clinical Inertia IS the Leading Cause of GDMT Underuse in HFrEF

September 20, 2024

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

News Daily News

Subcutaneous Furosemide Enables HF Patients to Address Congestion at Home

September 16, 2024

TCTMD’s Top 10 Most Popular Stories for August 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2024

September 03, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Presentation ESC 2024

Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis

Presenter: Pardeep S. Jhund

September 01, 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

News Conference News ESC 2024

Edoxaban Monotherapy Wins for AF and Stable Coronary Disease: EPIC-CAD

September 01, 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

News Conference News ESC 2024

Tri.Fr Trial Affirms Quality-of-Life Impact of Tricuspid TEER

August 31, 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presentation ESC 2024

Multicentric randomized evaluation of a Tricuspid valve Percutaneous Repair System (T-TEER) in the treatment of severe Tricuspid Regurgitation TRI.Fr

Presenter: Erwan Donal

August 31, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

News Daily News

FDA Approves Dropping Aspirin for HeartMate 3 LVAD Patients

August 21, 2024

CMS Announces Negotiated Medicare Prices for First 10 Drugs

News Daily News

CMS Announces Negotiated Medicare Prices for First 10 Drugs

Yael L. Maxwell

August 16, 2024

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

News Daily News

Only Small Minority of Eligible Patients Prescribed SGLT2 Inhibitors

Yael L. Maxwell

August 15, 2024

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

News Daily News

Scoring System Puts Focus on Medical Therapy Optimization in HFrEF

August 13, 2024

ACC Updates Pathway for Hospitalized HF Patients

News Daily News

ACC Updates Pathway for Hospitalized HF Patients

August 12, 2024

Acute HF Patients Live Longer When Seen by Specialists

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

ACC/AHA Update Performance, Quality Measures for HF Care

News Daily News

ACC/AHA Update Performance, Quality Measures for HF Care

August 08, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.